专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004076489A1 MODIFIED ANTIBODY 审中-公开
标题翻译：改良抗体
公开(公告)号：WO2004076489A1
公开(公告)日：2004-09-10
申请号：PCT/NO2004/000051
申请日：2004-02-25
申请人： MEDINNOVA AS , BOGEN, Bjarne , FREDRIKSEN, Agnete, Brunsvik , SANDLIE, Inger
发明人： BOGEN, Bjarne , FREDRIKSEN, Agnete, Brunsvik , SANDLIE, Inger
IPC分类号： C07K16/46
CPC分类号： C07K16/44 , A61K2039/505 , A61K2039/54 , C07K14/005 , C07K14/34 , C07K14/70578 , C07K14/7158 , C07K16/28 , C07K16/2833 , C07K2317/31 , C07K2317/622 , C07K2317/64 , C07K2319/40 , C12N9/1276 , C12N2740/16022 , C12N2740/16034 , C12Y207/07049
摘要： The present invention relates to a novel type of human recombinant antibody-like molecules useful in the treatment of i.e. multiple myeloma. These molecules, called Vaccibodies, bind APC and are able to trigger both T cell and B cell immune response. Moreover, Vaccibodies bind divalently to APC to promote a more efficient initiation of an immune response. Hence, a major purpose of the present invention is to induce a strong immune response to render adjuvants redundant. Vaccibodies comprise a dimer of a monomeric unit that consists of a targeting unit with specificity for a surface molecule on APC, connected through a hinge region and a Cγ3 domain to a antigenic unit in the COOH-terminal end; the latter being of e.g. B cell lymphoma or myeloma origin (Fig 1), although any origin is possible due to the cassette cloning system in the expression vector. The said molecule is capable of inducing an immune response against multiple myeloma, but extension to a general vaccination strategy for any polypeptid should be feasible. The present invention also relates to a DNA sequence coding for this recombinant antibody based molecule, to expression vectors comprising these DNA sequences, cell lines comprising said expression vectors, to treatment of mammals preferentially by immunization by means of Vaccibody DNA, Vaccibody RNA, or Vaccibody protein, and finally to pharmaceuticals and a kit comprising the said molecules.
摘要翻译：本发明涉及可用于治疗多发性骨髓瘤的新型类型的人重组抗体样分子。称为抗体的这些分子结合APC并能够触发T细胞和B细胞免疫应答。此外，疫苗抗体与APC二价结合以促进更有效地启动免疫应答。因此，本发明的主要目的是诱导强的免疫应答以使佐剂多余。抗体包含单体单元的二聚体，其由对APC上的表面分子具有特异性的靶向单元组成，所述靶向单元通过铰链区域连接，Cgamma3结构域连接至COOH末端的抗原单位; 后者是例如。 B细胞淋巴瘤或骨髓瘤来源（图1），尽管由于表达载体中的盒克隆系统，任何起源都是可能的。所述分子能够诱导针对多发性骨髓瘤的免疫应答，但对于任何多肽的扩展到一般的疫苗接种策略应该是可行的。本发明还涉及编码该重组抗体的分子的DNA序列，包含这些DNA序列的表达载体，包含所述表达载体的细胞系，优先通过Vaccibody DNA，Vaccibody RNA或Vaccibody进行免疫来治疗哺乳动物蛋白质，最后是药物和包含所述分子的试剂盒。

IPRDB

热门服务

关于我们

友情链接

联系方式